Fingerprints could replace needles for drug testing

NCT ID NCT07650136

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study evaluates a new device that detects codeine in fingerprint sweat. Researchers will compare its accuracy to standard lab methods. 144 healthy adults will provide fingerprints after taking codeine. The goal is to see if this quick, non-invasive method works reliably for drug screening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
codeine (measured in fingerprint sweat)
What this could lead to
If successful, this could provide a faster, less invasive way to screen for drug use using fingerprints instead of blood or urine.
What could go wrong
This is an early-stage device study focused on accuracy, not a treatment. It only tests for codeine, so results may not apply to other drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

135 "donors" and nine "operators." "Operators" represent end users who utilize the screening system in an office or work setting. These subjects do not have to possess special training in laboratory methods. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening. Sufficient numbers of subjects will be screened to attain those numbers and to ensure that at least 33% of each sex and at least 15% Black subjects are included as "donors" in the study. At least two sites will have both sexes represented among "operator" subjects. Sites may recruit sufficient alternate subjects to ensure achievement of those numbers. Subjects will be selected from members of the community at large.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Able to provide informed consent 2. Completed the screening process within 30 days prior to dosing. 3. Healthy male and non-pregnant female subjects at the time of dosing. 4. Body mass index (BMI) from 18.0 kg/m2 to 32.0 kg/m2, inclusive 5. Weigh at least 60 kg. 5. Females of childbearing potential must be willing to practice an acceptable form of contraception, and have a negative urine pregnancy test on admission to the treatment phase of the study. 6\. Males must agree to practice an acceptable form of contraception 7. Judged by the Investigator and/or designee to be in good health as documented by the medical history, and vital sign assessments. Exclusion Criteria: 1. Unwilling or unable to provide informed consent. 2. More than three digits absent from the hands due to congenital or accidental cause(s). 3. Reports receiving any investigational drug within 30 days prior to dosing. 4. Reports a clinically significant illness during the 30 days prior to the in-clinic portion of the study (as determined by the Investigator). 5. Reports any personal history of substance abuse (including drug/alcohol abuse or addiction) or mental illness (e.g. major depression) within one year prior to screening visit. 6. Is pregnant (females only). 7. Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator. 8. Reports history of respiratory depression (e.g., sleep apnea). 9. Reports history of reaction to codeine (e.g., nausea, allergy). 10. Current severe hypotension (i.e., systolic blood pressure \<90 mmHg). 11. Reports known or suspected gastrointestinal obstruction including, paralytic ileus. 12. Reports current presence of acute bronchial asthma/ upper airway obstruction. 13. Reports a history of clinically significant allergies, including food or drug allergies, as judged by the Investigator. 14. Reports history or current condition of adrenal insufficiency. 15. Reports history or current condition of renal disease. 16. If, in the opinion of the Investigator, the subject is not suitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug abuse illicit are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CenExel Clinical Research

    RECRUITING

    Marlton, New Jersey, 08053, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.